ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

Learn more about:
Related Clinical Trial
Cardiac Involvement in Wilson’s Disease Oral Health and Wilson’s Disease: SOMAWI Gandouling in the Treatment of Wilson’s Disease International Wilson’s Disease Patient Registry (iWilson Registry) Wilson France Register Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease Clinical Features and Outcome of Wilson’s Disease With Generalized Epilepsy in Chinese Patients Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease rTMS in Wilmson Diasease Dysarthria Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

Official Title

A Feasibility Clinical Trial of the Magnetic Resonance Guided Focused Ultrasound (MRgFUS) for the Management of Treatment-Refractory Movement Disorders

Brief Summary

      The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool
      for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients
      with treatment-refractory symptoms of movement disorders.

Detailed Description

      The purpose of this study is to evaluate the safety and initial effectiveness of MRI-guided
      focused ultrasound thermal ablation of a designated area in the brain of patients suffering
      from movement disorder symptoms:

        -  FUS under MRI-guidance and MRI-based thermometry can be safely delivered to patients
           suffering from treatment-refractory movement disorders through an intact human skull
           with a low risk of transient adverse effects as evaluated during follow-up of up to

        -  A pre-defined target volume inside the brain can be accurately ablated, as demonstrated
           on post-treatment MRI.

        -  Lesions generated with ExAblate Neuro will result in clinical effects that are similar
           to those seen with ablative procedures using other surgical techniques (e.g. RF

Study Type


Primary Outcome

Severity of Device and Procedure Related Complications


Movement Disorders


Transcranial ExAblate System

Study Arms / Comparison Groups

 Transcranial ExAblate System
Description:  Transcranial ExAblate System (MRgFUS)


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

May 2015

Completion Date

December 2021

Primary Completion Date

December 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Men and women, between 18 and 85 years, inclusive.

          -  Subjects who are able and willing to give consent and able to attend all study visits.

          -  A movement disorder symptom that has been deemed treatment-refractory by a movement
             disorder neurologist, including:

             o akathisia, akinesia, athetosis, bradykinesia, chorea, dystonia, tremor, myoclonus,
             dyskinesia, spasms, tics

          -  Medication-refractoriness as determined by an adequate dose and duration of standard
             movement disorders treatment as determined by a specialist neurologist (e.g. a trial
             of primidone and propranolol for ET)

          -  Able to communicate sensations during the ExAblate Neuro treatment

          -  Stable doses of all medications for 30 days prior to study entry and for the duration
             of the study.

        Exclusion Criteria:

          -  Patients with unstable cardiac status including:

               -  Unstable angina pectoris on medication

               -  Patients with documented myocardial infarction within six months of protocol

               -  Congestive heart failure requiring medication (other than diuretic)

               -  Patients on anti-arrhythmic drugs

          -  Severe hypertension (diastolic BP > 100 on medication)

          -  Patients with standard contraindications for MR imaging such as non-MRI compatible
             implanted metallic devices including cardiac pacemakers, size limitations, etc.

          -  History of abnormal bleeding and/or coagulopathy (including deep venous thrombosis)

          -  Cerebrovascular disease (multiple CVA or CVA within 6 months)

          -  Symptoms and signs of increased intracranial pressure (e.g. headache, nausea,
             vomiting, lethargy, and papilledema)

          -  Untreated, uncontrolled sleep apnea

          -  Active or suspected acute or chronic uncontrolled infection

          -  History of intracranial hemorrhage

          -  Individuals who are not able or willing to tolerate the required prolonged stationary
             supine position during treatment

          -  Are participating or have participated in another clinical trial in the last 30 days

          -  Patients unable to communicate with the investigator and staff.

          -  Presence of any other neurodegenerative disease like multisystem atrophy, progressive
             supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.

          -  Patients with a history of seizures within the past year

          -  Patients with psychiatric illness that are not well controlled. Any presence of
             psychosis will be excluded.

          -  Patients with risk factors for intraoperative or postoperative bleeding (platelet
             count less than 100,000 per cubic millimeter) or a documented coagulopathy

          -  Patients with brain tumors

          -  Any illness that in the investigator's opinion preclude participation in this study.

          -  Pregnancy or lactation.

          -  Patient is unable to provide his own consent for any reason.

          -  Legal incapacity or limited legal capacity.

          -  Patients who have DBS or a prior stereotactic ablation of the basal ganglia

          -  History of immunocompromise, including patient who is HIV positive

          -  Known life-threatening systemic disease




18 Years - 85 Years

Accepts Healthy Volunteers



Andres Lozano, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor


Study Sponsor

Andres Lozano, MD, Principal Investigator, Sunnybrook Health Sciences Centre

Verification Date

August 2021